aTYR PHARMA INC — Director's Dealing 2021

May 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-05-21

Reporting Person: CLARKE JOHN K (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-21	Common Stock	S	2500	$4.34	Disposed	108083	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7492	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These shares were sold to cover fund expenses.

F2: These shares are owned directly by CHP II, LLP ("CHP"). The general partner of CHP is CHP II Management, LLC, ("CHP Management"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose.